Recent News

• 09.17.2025 - Vaxart Appoints W. Mark Watson as Lead Independent Director
• 09.17.2025 - Vaxart Appoints W. Mark Watson as Lead Independent Director
• 09.17.2025 - Vaxart Appoints W. Mark Watson as Lead Independent Director
• 09.10.2025 - Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate
• 09.10.2025 - Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate
• 09.10.2025 - Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate
• 09.08.2025 - Vaxart at the H.C. Wainwright 27th Annual Global Investment Conference
• 09.08.2025 - Vaxart at the H.C. Wainwright 27th Annual Global Investment Conference
• 09.08.2025 - Vaxart Announces Adjournment of Special Meeting of Stockholders
• 09.08.2025 - Vaxart Announces Adjournment of Special Meeting of Stockholders

Recent Filings

• 09.10.2025 - PX14A6G Notice of exempt solicitation submitted by non-management
• 09.08.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 09.08.2025 - 8-K Current report
• 09.08.2025 - EX-99.1 EX-99.1